Shenzhen Capital Group

Shenzhen Capital Group is one of the largest government-originated venture organizations in China, with a multi-decade history of channeling capital into hard technology, advanced manufacturing, and life sciences. Operating from Shenzhen, the firm functions as much as a platform as a single fund, with multiple vehicles and partnerships that allow it to participate across stages and sectors at meaningful scale.

The healthcare focus covers medical devices and MedTech, biotech, and AI/ML in healthcare. The portfolio orientation reflects China’s industrial priorities: domestic medical device manufacturing, biotech pipelines that reduce import dependence, and AI-enabled healthcare infrastructure that can be deployed across large hospital networks. The firm is comfortable backing companies whose product cycles span years, including those that require significant capital expenditure for manufacturing capacity, and it is unusually willing to support companies through extended development timelines compared with most independent venture firms.

Check sizes run from $5M to $25M, with activity across Series A, Series B, Series C, and growth rounds. That stage range positions the firm primarily as a follow-on participant in early rounds and as a potential lead in later ones, with the capacity to write significantly larger checks through related vehicles when warranted. Founders should expect a process that reflects both venture and policy considerations, with diligence that covers commercial fundamentals, technology positioning, and alignment with Chinese industrial strategy.

The team is large and includes investors with backgrounds in finance, engineering, life sciences, and public policy. Governance expectations tend to be formal, and the firm is comfortable taking active board roles and engaging on strategic questions. Reporting cadences are typically more demanding than founders coming from independent venture environments may expect, and the firm is candid about the regulatory and political considerations that shape its investment activity.

For founders, working with Shenzhen Capital Group means an investor with significant capital depth, strong relationships across Chinese hospital systems and manufacturing supply chains, and the ability to support companies through capital-intensive scaling. Post-investment support tends to focus on commercial introductions inside China, manufacturing partnerships, and follow-on capital from related vehicles or co-investors. The firm is a less natural fit for companies whose primary market is outside China, particularly those with sensitive cross-border data or technology considerations, and founders should think carefully about how a strategic Chinese government-linked investor on the cap table affects their international fundraising and partnership options. It is a strong fit for technically credible teams whose business is anchored in China, whose growth depends on access to domestic clinical and manufacturing infrastructure, and who want an investor with the scale to support multi-year capital needs.